The United States has one of the world's largest cannabis markets but remains a minor participant in international medical cannabis trade. Federal medical rescheduling could create new opportunities, but U.S. operators still face established foreign competitors, pharmaceutical quality standards, permitting requirements, logistics costs, and growing domestic production in importing markets.

Canada remains the world's largest medical cannabis exporter, but growing European production is beginning to challenge its lead. Germany's expanding market, Portugal's rapid export growth, stricter pharmaceutical standards, reimbursement changes, and new lower cost suppliers are reshaping international cannabis competition.

Canada still supplies most of Australia's imported medical cannabis, but Thailand rapidly gained market share in 2025 while Australian domestic production reached a new high. The shift shows an increasingly competitive supply chain where pricing, quality standards, contracts, inventory, and reliable international market access matter more.

Thailand issued tougher cannabis enforcement guidelines with 30 to 90 day license suspensions and possible revocation for repeat or serious violations. The bigger lesson is that Thailand is tightening its cannabis market around prescriptions, reporting, license display, advertising limits, online sales bans, and controlled medical use.

Morocco’s legal cannabis industry now has more than 140 cannabis based products manufactured and officially registered with the Moroccan Agency for Medicines and Health Products. The bigger lesson is that Morocco is moving from cultivation potential into regulated product manufacturing, export readiness, and international supply chain relevance.

Brazil set a new record for medical cannabis imports in March 2026, with more than 61,000 import authorizations granted in the first quarter and 23,199 in March alone. The bigger lesson is that Brazil is becoming a serious medical cannabis growth market, but import dependence, patient authorization rules, and distribution structure will decide who actually captures the opportunity.

Organigram is using Germany as its first real step into broader European medical cannabis growth. The bigger lesson for operators is that international expansion still depends on local compliance, strong distribution partners, and the patience to build market by market.